Pharmaceutical companies Eli Lilly and Company (NYSE:LLY) and EVA Pharma announced on Tuesday that the Egyptian Drug Authority has approved the insulin glargine injection manufactured by EVA Pharma in Egypt.

This marks a significant milestone in the companies' collaboration to expand access to affordable insulin in low- to middle-income countries.

The partnership, launched in 2022, aims to provide high-quality, affordable insulin to one million people annually by 2030. Lilly has been supplying the active pharmaceutical ingredient to EVA Pharma at a reduced price and providing technology transfer to enable local manufacturing.

The collaboration aligns with Lilly's 30x30 initiative, which aims to improve health access for 30 million people living in resource-limited settings annually by 2030.